Multiply Labs

We’re thrilled to announce our collaboration with Legend Biotech, focused on automating cell therapy manufacturing! Excited to work with some of the best scientists in the field.  Through this collaboration, Legend Biotech will evaluate our robotic technologies, and secure priority access to those automated systems. The Multiply Labs approach to automating cell therapy manufacturing - as seen in this video - is rooted in the promising results of our  peer-reviewed study in Cytotherapy, which highlighted statistical equivalence between manual and automated cell expansion processes. This collaboration will help showcase the potential of our flexible automation solutions, bringing us closer to our vision of reducing labor costs and increasing manufacturing throughput. Learn more about the news here: https://bit.ly/3TG8JsG   #CellTherapy #Robotics #Innovation #Pharma #BioTech

Vials are at the core of every cell therapy manufacturing process—yet until now, vial handling has remained a manual task. 🔬🤖 In biomanufacturing, reagents like growth factors, viral vectors, and CRISPR reagents are typically supplied in vials. Similarly, QC samples are oftentimes stored and output in vials. Transferring these critical materials has long required scientists to perform a manual, syringe-based process in a fume hood–even if other process steps are automated. Now, Multiply Labs’ robotic systems change that. Our technology is the first in the industry to fully automate vial handling within GMP-grade, closed-system manufacturing—completely eliminating the need for process workarounds or costly manual interventions. 🎥 In this video, our Senior Scientist Sudeshna Sadhu demonstrates the difference: side by side, you’ll see the traditional manual process versus our robotic solution. The future of scalable cell therapy automation starts with vial automation—and we’re leading the way. #Biomanufacturing #Automation #Pharma #Robotics

Automation in cell therapy manufacturing is evolving rapidly—and as our CEO Fred (Federico) Parietti shared in Thermo Fisher Scientific’s recent webinar, the biggest advancements will be driven by CGT developer demand. We discussed key opportunities such as: ✅ Expanding automation to more unit operations, ensuring compatibility with the instruments and reagents developers already use. ✅ Addressing new bottlenecks—like loading and unloading—created by faster robotic systems. Watch the clip to hear Fred’s insights on where the industry is headed! #CGT #Biotech #CellTherapy #Automation 

Safety isn’t an afterthought—it’s built into everything we do. We’re advancing automation with cutting-edge robotics designed for seamless and safe human collaboration in pharma manufacturing. That’s why we’ve teamed up with Mediate Srl to integrate the most advanced proximity-based safety sensors into our robotic systems. These sensors ensure that our robots are always aware of their surroundings, keeping operators safe without compromising efficiency. Watch our Senior Robotics Engineer, Varun Bhatia and the Mediate Team, Marcello Chiurazzi and Emiliano Cutolo, demo this breakthrough in action! 🤖 #Pharma #Automation #Bioprocessing #Robotics

Cell counting is a crucial step in bioprocessing for next-gen therapies, ensuring that cells are viable through critical parts of the manufacturing process. Traditionally, it's a lengthy manual task that requires extreme precision, resulting in bottlenecks that hinder scaling operations. At Multiply Labs, we applied our flexible robotic technology to automate this critical process step, transforming a once-manual step into one seamless, integrated into an automated workflow. By integrating off-the-shelf cell-counters that are already used in approved processes, our robots can not only perform cell counting but also make informed decisions automatically, boosting efficiency and control downstream - all without changing the manufacturing process. Why does this matter? Automating cell counting isn’t just about speeding things up – it’s about improving consistency, reducing errors, and empowering robots to take action based on real-time data. It’s one more step toward the future of fully automated bioprocessing. Check out the video featuring our senior scientist, Sudeshna Sadhu, to learn about what it takes to perform a manual cell count and see how we have automated it! 🎥 Want to see more of Multiply Labs' videos? Check us out on YouTube 🔗https://lnkd.in/g4pedp7i #Biotech #Automation #Robotics #Bioprocessing

📢 Join us for a deep dive into the future of Cell and Gene Therapy (CGT) manufacturing! Our CEO, Fred (Federico) Parietti, will be joining David Shaw and Carl Dargitz for Thermo Fisher Scientific’s webinar tomorrow to discuss how automation can scale production while maintaining quality and safety—without changing existing processes. 🗓 Thursday, March 6, 2025 ⏰ 08:00 PST | 11:00 EST | 16:00 GMT | 17:00 CET 🔗 Register now: https://lnkd.in/g_jAWwBP Let’s talk about modular automation, streamlined workflows, and how we can make CGT manufacturing more efficient. See you there! #CGT #Biotech #CellTherapy #Automation #Webinar

Cell therapy manufacturing is at a crossroads. Scaling production requires automation, but for automation to be trusted, it must be validated. Without real-world data, automation remains a promise rather than a proven solution. Today, most cell therapies rely on costly manual processes that limit scalability and introduce potential sterility risks. The future depends on automation, but not all automation solutions are created equal. Our cofounder and CSO Alice Melocchi partnered with scientists at the Stanford GMP Facility: Laboratory for Cell and Gene Medicine, including Steven Feldman, and our Senior Advisor Jonathan H. Esensten, M.D., Ph.D., M.D., Ph.D., and Director of the Advanced Biotherapy Center (ABC), Sheba Tel HaShomer City of Health, on a newly published paper in the Journal of Controlled Release. This study takes a data-driven look at the future of automation in cell therapy, answering questions such as: 🔹 How do different automation approaches (modular vs. all-in-one) impact flexibility? 🔹 Can automation reduce operator involvement while maintaining sterility? 🔹 What strategies best enable scalability without compromising quality? At Multiply Labs, we believe automation must be proven—not just promised. We are proud to be the only company with peer-reviewed data proving that our robotics manufacturing system achieves results equivalent to manual processes in cell therapy. Automation isn’t just about speed—it’s about ensuring consistency, sterility, and efficiency at scale. And for automation to be trusted, it must be backed by real-world validation. Read more at https://lnkd.in/gUaSV9gh #Biotech #CellTherapy #Automation #Manufacturing #Robotics

What if instead of building more clean rooms, we focused on building better processes? According to Multiply Labs Senior Advisor Jonathan H. Esensten, M.D., Ph.D., and Director of the Advanced Biotherapy Center (ABC), Sheba Tel HaShomer City of Health at Sheba Medical Center, Tel Hashomer, “We may have reached peak clean room.” He proposes that instead of continuously building more Grade B clean rooms to accommodate human operators, the focus should shift to robotics and closed systems—allowing high-quality manufacturing to take place outside of highly classified environments. This shift toward automation also helps address challenges in standardization. While consistent materials, reagents, and equipment are critical, manual processes aren’t always consistent, and reliance on single suppliers can introduce risks. Strategic partnerships, like Multiply Labs’ collaboration with GenScript, are key to overcoming these obstacles. Automation is also a game-changer for academic groups like Dr. Esensten’s at Sheba Medical Center where automated systems enable distributed manufacturing models, making cell and gene therapies more accessible worldwide. Multiply Labs is proud to work alongside leaders like Dr. Esensten to help scale and transform next-gen biological therapy manufacturing. The future is automated, scalable, and more accessible than ever. 🚀 #CellTherapy #GeneTherapy #Automation #Biomanufacturing #Robotics #Pharma

What do engineers often get wrong about science? And what do scientists often misunderstand about engineering? 🚨 The first episode of our podcast, Cell Mates, is here! 🚨 In this debut episode, we brought together Fred (Federico) Parietti, PhD, robotics engineer and CEO of Multiply Labs, and Sanket Acharya, PhD, scientist and senior director of corporate development at GenScript, to explore how these two worlds collide—and come together—to shape the future of pharma manufacturing. 💡 It’s not just a conversation; it’s a deep dive into collaboration, innovation, and the power of bridging disciplines! Our mission is to bring science and engineering together to build the future of pharma manufacturing, one conversation at a time! Listen to the full episode on ➡️ YouTube: https://lnkd.in/g78W699S ➡️ Spotify: https://lnkd.in/gbgvNagr ➡️ Apple Podcasts: https://lnkd.in/gm84Grab ➡️ Amazon Music: https://lnkd.in/gEeRiWJy #CellMatesPodcast #Pharma #Automation #CellTherapy #AI #Robotics #PodcastLaunch

What’s the biggest difference between how scientists and engineers think? 🤔 What happens when you put scientists and engineers in the same room to brainstorm solutions to some of pharma’s biggest challenges? We explore these very questions and more in our NEW podcast: Cell Mates, the podcast that is building the future of pharma automation, one conversation at a time! 🎧You won’t want to miss this... The first episode, featuring special guest Sanket Acharya, PhD from GenScript, drops this Thursday! EDIT: First episode is out! ➡️ YouTube: https://lnkd.in/g78W699S ➡️ Spotify: https://lnkd.in/gbgvNagr ➡️ Apple Podcasts: https://lnkd.in/gm84Grab ➡️ Amazon Music: https://lnkd.in/gEeRiWJy #CellMatesPodcast #Pharma #Automation #CellTherapy #AI #Robotics #Podcast